BofA warns Fed risks policy mistake with early rate cuts
MENLO PARK, CA—Aaron Freidin, Chief Financial Officer of GRAIL, Inc. (NASDAQ:GRAL), has recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Freidin sold 41,150 shares of common stock on May 2, 2025. The shares were sold at a weighted average price of $33.93, totaling approximately $1.4 million. The transaction comes as GRAL stock has shown remarkable strength, posting a 150% return over the past year and trading near $34, significantly above its 52-week low of $12.33.
Following this transaction, Freidin retains ownership of 294,020 shares in the company. The sale was part of a block trade executed in multiple transactions, as noted in the filing. GRAIL, Inc., known for its innovative cancer detection technologies, continues to attract investor attention, with a market capitalization of $1.26 billion and an overall GOOD financial health score according to InvestingPro. The company is scheduled to report earnings on May 13, 2025, where investors will closely monitor its cash utilization and growth trajectory. For deeper insights into GRAL’s valuation and growth prospects, InvestingPro offers comprehensive analysis with 10 additional key insights available.
In other recent news, Grail Inc. reported a 26% year-over-year increase in revenue for the fourth quarter of 2024, totaling $38.3 million. Despite a net loss of $97.1 million, the company improved its financial position by reducing its quarterly loss by 48%. For the full year, Grail’s revenue reached $125.6 million, marking a 35% increase from 2023, driven largely by a 45% rise in screening revenue from the sale of 137,000 Galleri tests. In addition, Canaccord Genuity initiated coverage of Grail with a Buy rating and set a 12-month price target of $32, indicating confidence in the company’s potential growth. The firm acknowledged the long-term potential of Grail’s multi-cancer early detection tests but also noted regulatory and market acceptance challenges. Grail launched an enhanced version of its Galleri test, which is now included in the U.S. Military’s TRICARE health insurance program for eligible patients, expanding its reach. These developments underscore Grail’s strategic advancements in product development and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.